111391-32-3

Basic information

• Product Name: 2-Propen-1-one, 1-(2-hydroxyphenyl)-3-[4-(phenylmethoxy)phenyl]-
• CAS NO: 111391-32-3
• Molecular Formula: C22H18O3
• Molecular Weight: 330.383
• Mol File: 111391-32-3.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2-Propen-1-one, 1-(2-hydroxyphenyl)-3-[4-(phenylmethoxy)phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propen-1-one, 1-(2-hydroxyphenyl)-3-[4-(phenylmethoxy)phenyl]-(111391-32-3)
• EPA Substance Registry System: 2-Propen-1-one, 1-(2-hydroxyphenyl)-3-[4-(phenylmethoxy)phenyl]-(111391-32-3)

Safety Data

• Hazardous Substances Data: 111391-32-3(Hazardous Substances Data)

Upstream product

• 4397-53-9 p-benzyloxybenzaldehyde 
• 118-93-4 o-hydroxyacetophenone 

Downstream Products

• 111391-62-9 2-(4-benzyloxy-phenyl)-3-methoxy-chromen-4-one 
• 111391-31-2 2-(4-hydroxyphenyl)-3-methoxy-4H-chromen-4-one 
• 13323-66-5 2',4-dihydroxychalcone 
• 102468-65-5 2-(4-(benzyloxy)phenyl)-3-hydroxy-4H-chromen-4-one 

Relevant articles and documents

COMPOSITION FOR TREATING DIABETES AND METABOLIC DISEASES AND A PREPARATION METHOD THEREOF

Disclosed is a chalcone composition for treating diabetes and metabolic syndromes. In particular, the chalcone compound bound with 2-halogen in ring A significantly decreases the blood glucose level in the in vitro anti-diabetic effect experiment. In the in vivo animal model, the leading chalcone compound can prevent the progression of diabetes and control the blood glucose level, and there is no significant difference in the gains in body weight. Throughout the seven-week administration, there are no hepatic or renal toxicity observed.

Inhibitory activity of prostaglandin E2 production by the synthetic 2′-hydroxychalcone analogues: Synthesis and SAR study

A series of 2′-hydroxychalcones has been synthesized and screened for their in vitro inhibitory activities of cyclooxygenase-2 catalyzed prostaglandin production from lipopolysaccharide-treated RAW 264.7 cells. Structure-activity relationship study suggested that inhibitory activity against prostaglandin E2 production was governed to a greater extent by the substituent on B ring of the chalcone, and most of the active compounds have at least two methoxy or benzyloxy groups on B ring. The relationship between chalcone structures and their PGE2 inhibitory activities was also interpreted by docking study on cyclooxygenase-2.

Synthetic chalcones, flavanones, and flavones as antitumoral agents: Biological evaluation and structure-activity relationships

A series of synthetic chalcones, flavanones, and flavones has been synthesized and evaluated for antitumor activity against the human kidney carcinoma cells TK-10, human mammary adenocarcinoma cells MCF-7 (estrogen receptor-positive), and human colon adenocarcinoma cells HT-29. The most active series is the chalcone ones with the best results against TK-10 and HT-29 cells. Fourteen out of 53 analyzed compounds resulted very active against at least two of the studied tumoral cells. Alkaline single cell gel electrophoresis, comet assay, was performed as a study of the chromosomal aberrations promoted by the compounds on normal cells. Four active and two inactive chalcones were studied in the comet assay against normal human kidney cells (HK-2). A structure-activity relationship analysis of these compounds was performed and for 4- and 3,4-disubstituted derivatives a quantitative correlation was obtained in the case of anti-HT-29 activity.